Purple Biotech Ltd (NASDAQ: PPBT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Purple Biotech Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Purple Biotech Reports Third Quarter 2024 Financial Results
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics